Arqule

NASDAQ

- -

- -

- -

- -

- -

- -

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. Its lead product candidate is tivantinib (ARQ 197), a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer and non-small cell lung cancer; Phase II clinical trial for the treatment of mesothelioma and kidney cancer; and Phase I clinical trial for the treatment of pediatric tumors, as well as has completed Phase II clinical trial for the treatment of colorectal cancer. The company’s early clinical-stage products include ARQ 092, an inhibitor of the AKT serine/threonine kinase in Phase Ib clinical trials; ARQ 087, a multi-kinase inhibitor of the fibroblast growth factor receptor (FGFR) family Phase II clinical trial for patients with intrahepatic cholangiocarcinoma and FGFR translocations, amplification, and mutations; and ARQ 761, an intravenously administered analogue of Beta-lapachone, which is Phase 1b clinical trial used as a promoter of NQo1-mediated programmed cancer cell necrosis. Its pre-clinical development program also includes ARQ 751, a next-generation inhibitor of AKT. The company has co-development and co-commercialization agreement with Daiichi Sankyo Co., Ltd.; license agreement with Kyowa Hakko Kirin Co., Ltd.; collaborative research and development agreement with Beryllium Development Corp.; and collaboration agreement with the National Human Genome Research Institute of the NIH. Arqule, Inc. was founded in 1993 and is headquartered in Burlington, Massachusetts.